Skip to main content
OpenTrials
Completed

NCT Number: NCT01951222

Bronchodilator Properties and Safety in Asthma

Recent large clinical studies have demonstrated the interest of LAMA therapy in the management of asthma, when compared to LABA.

V0162 is a compound with a very long lasting bronchodilator effect when compared to reference treatment in non-clinical models and in COPD patients. Secondary properties of V0162 (i.e.H1/H4 and PDE IV-inhibition) could enhance the efficacy of this antimuscarinic compound and could bring option in the treatment obstructive lung disease. The objective of the study is to assess the bronchodilator properties of V0162 during 8 days in adult patients with asthma usually treated with ICS and LABA. The study is a randomised, double-blind, placebo-controlled, 3-period crossover, preceded by an open-label active-control period before randomisation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Bronchial Diseases Chronic Disease Disease Attributes Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiration Disorders Respiratory Aspiration Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

CRO

Gauting, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18 to 65 years-old.
  • 18 ≤ BMI <30 kg/m².
  • Clinical history consistent asthma, in the judgement of the investigator.
  • Asthma controlled or partly controlled according to GINA 2012 criteria:
  • Asthma treated by ICS and LABA (fixed-dose combination or free combination) at stable dose for at least 3 months.
  • Able to replace the usual ICS and LABA therapy by ICS at the usual dose regimen and salbutamol as needed.
  • Able to stop salbutamol at least 6 hours before a study visit.
  • Able to perform at least 3 acceptable and reproducible FEV1 and FVC measurements according to ERS/ATS 2005 recommendations.

Exclusion criteria

  • Clinically significant respiratory conditions other than asthma (e.g. pneumonia, pneumothorax, atelectasis, bronchiectasis, chronic bronchitis, COPD, emphysema, pulmonary arterial hypertension, pulmonary fibrosis,etc.).
  • Upper or lower respiratory tract infection within 4 weeks.
  • Exacerbation (requiring oral corticosteroids or hospitalization) within 3 months.
  • Current smoker or former smoker less than 6 months or total lifetime smoking history greater than 10 pack-years.
  • Intolerance to salbutamol.
  • Intolerance to tiotropium (or any other atropine-derived compound).
  • Intolerance to one of the ingredients of the study product
  • Severe hepatic impairment, moderate to severe renal impairment, epilepsy, narrow angle glaucoma, gastrointestinal obstruction, moderate to severe prostatic hypertrophy, bladder neck obstruction.
  • Any acute or chronic disease that will not allow the participation in the study, in the judgement of the investigator.
  • Clinically relevant physical examination abnormality.

Treatment and study plan

V0162

Drug

Placebo

Other

Primary outcomes

  1. Normalised AUC 0-24h of FEV1 at day 8 of treatment period

    Time frame: At the 8th day of treatment period

    FEV1 assessed by spirometry

Secondary outcomes

  1. Parameters of the pulmonary function

    Time frame: Day 1 and Day 8 of treatment period

    as well as the following criteria assessed the first day and the last day of each treatment period and the difference between the last day and the first day within each treatment periodadjusted for placebo effect:

    • the normalised AUC0-9h of FEV1 (L),
    • the normalised AUC0-12h of FEV1 (L),
    • the peak of FEV1 (L) which is the higher observed post-dosing value,
    • the trough of FEV1 (L) which is the last measurement before the next dosing (i.e. t24h),
    • the normalised AUC0-9h,AUC0-12h, AUC0-24h, peak and trough of FVC, MEF25, MEF50, MEF75, and MEF25-75.

  2. PEF

    Time frame: Morning and evening from Day 1 to day 8 of treatment period

    PEF measured using a peak-flow meter

  3. Dyspnoea

    Time frame: Day 1 to Day 8 of treatment period

    The criteria will be the normalised AUC0-9h,AUC0-12h, and AUC0-24h of the dyspnoea measurements(mm) assessed the first and the last day of each treatment period, and the difference between the last and the first day within each treatment period.

  4. Vital signs

    Time frame: Visit 2, and at Visit 3 to Visit 10 (within 30 min pre-dose and 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 24 h post-dose during the in-clinic visits) and at Visit 11

  5. 12-lead standard ECG

    Time frame: at Visit 1, at Visit 3 to Visit 10 (within 30 min pre-dose and 15 min, 1 h, 6 h, 24 h post-dose) and at Visit 11

  6. Holter-ECG

    Time frame: At Visit 3 to Visit 10 : from 30 min pre-dose to 12 hours post-dose

  7. Clinical laboratory tests (haematology, biochemistry, urinalysis)

    Time frame: Visit 1 and Visit 11

  8. AEs

    Time frame: From Visit 1 to Visit 11

  9. Normalised AUC 0-24h of FEV1 at Day 1 of treatment period

    Time frame: The first day of treatment period

    FEV1 assessed by spirometry

  10. Difference between day 8 and first day of treatment period in normalised AUC 0-24h of FEV1

    Time frame: Difference between day 8 and first day of treatement period

    FEV1 assessed by spirometry

Sponsors and collaborators

Lead sponsor

Pierre Fabre Medicament

Industry

Registry information

Official study title

Bronchodilator Properties and Safety of a Repeated Dose of V0162 in Asthma.

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Sep 26, 2013
Registry last updated
Sep 17, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.